獸醫內分泌學市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

2024 年全球獸醫內分泌市場規模為 4.145 億美元，預計到 2034 年將以 6.5% 的複合年成長率成長至 7.703 億美元。隨著動物（尤其是寵物）中庫欣氏症候群、糖尿病和阿狄森氏症等荷爾蒙失調疾病的發生率不斷上升，該市場發展勢頭強勁。寵物擁有率的上升，加上人類與動物之間聯繫的加深，正在推動全球對寵物醫療保健的需求。即時診斷技術的出現擴大了先進療法的可及性，加上人們對慢性動物疾病認知的不斷提高，內分泌學已成為獸醫學中最具活力的領域之一。治療方法的不斷改進以及伴侶動物和家畜對長期疾病管理的需求，正在進一步塑造市場。

隨著政府和私營部門利益相關者致力於加強動物保健體系，亞太和拉丁美洲新興市場對獸醫服務和基礎設施的快速投資也正在促進產業擴張。獸醫診所、診斷實驗室和遠距醫療能力的資金投入增加，正在改善包括內分泌科在內的專科護理的可近性。伴侶動物飼養量的增加，加上寵物預防和慢性疾病管理的趨勢，正在加速對先進荷爾蒙療法和診斷工具的需求。本地生產設施、獸醫專業人員培訓以及與跨國製藥公司的合作，也為這些高潛力地區的長期成長和市場滲透奠定了堅實的基礎。

2024年，獸醫內分泌學市場中的藥物治療細分市場佔76.5%的佔有率。該細分市場的領先地位源於其價格實惠、長期使用以及在治療常見動物內分泌疾病方面療效穩定等特點，使其被廣泛採用。甲狀腺功能減退症、糖尿病和腎上腺功能障礙等慢性疾病通常需要持續的醫療干預。這些治療中使用的藥物受益於改進的藥物配方，從而提高了治療效果並提高了寵物主人的依從性。隨著早期診斷變得越來越常規，尤其是在城市診所，基於藥物的治療方案仍然是大多數地區的主要治療方案。

在內分泌疾病類型中，糖尿病細分市場到2034年的複合年成長率將達到6.4%。一個關鍵因素是寵物肥胖率的上升，尤其是老年貓狗，這與過度餵食和缺乏運動有關。這催生了對先進糖尿病管理產品和護理方案的持續需求。科技顯著改善了疾病管理，長效胰島素製劑和自動血糖監測設備等工具如今能夠更精確、更持續地控制動物的糖尿病症狀。這些創新提升了實務工作者的信心，也增強了寵物主人參與治療的意願。

2024年，美國獸醫內分泌市場產值達1.551億美元。美國在該市場的領先地位主要歸功於其早期採用新技術，例如動態血糖監測（CGM）和針對激素紊亂的遠距醫療服務，以及專注於內分泌學的獸醫專家的廣泛存在。犬甲狀腺功能減退症和貓糖尿病病例的增加，持續推高了對診斷和標靶治療的需求。此外，人們對寵物肥胖相關疾病的認知不斷提高，以及完善的製藥和監管環境，有助於美國保持市場主導地位。擁有大量產品組合和研發管線的公司正在加速獸藥核准，並推出客製化治療方案，以滿足這些日益成長的需求。

引領獸醫內分泌市場的主要參與者包括禮來動物保健、勃林格殷格翰、默克、德克製藥、碩騰、MedPharm 動物保健、Med-Pharmex、維克、Kela Health、Vivaldis 動物保健和 Nextmune。這些公司在不斷創新的同時，也加強了其全球分銷和產品線。領先的獸醫內分泌公司正積極拓展其產品線，投資長效製劑和先進的給藥系統，以提高治療順從性。他們也透過策略夥伴關係和收購，增強在服務不足和高成長地區的影響力。各公司正專注於將診斷和治療相結合，提供全面護理解決方案，尤其針對糖尿病等慢性內分泌疾病。該公司專注於獸醫培訓計畫和寵物主人宣傳活動，以提高早期診斷和治療的採用率。遠距獸醫平台和行動診斷等數位工具正擴大用於改善醫療服務並簡化護理流程。

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

• 產業生態系統分析
• 產業衝擊力
  • 成長動力
    • 伴侶動物和牲畜內分泌失調的盛行率不斷上升
    • 增加寵物擁有量和寵物人性化
    • 寵物肥胖發生率上升
    • 監管支持和增加藥品核准
  • 產業陷阱與挑戰
    • 治療費用高且治療時間長
    • 獸醫內分泌專家有限
  • 市場機會
    • 伴侶動物數量成長和慢性疾病負擔
    • 即時診斷和家庭診斷的進步
• 成長潛力分析
• 監管格局
• 技術格局
  • 當前的技術趨勢
  • 新興技術
• 定價分析
• 未來市場趨勢
• 差距分析
• 波特的分析
• PESTEL分析

第4章：競爭格局

• 介紹
• 公司市佔率分析
  • 全球的
  • 北美洲
  • 歐洲
  • 亞太地區
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 關鍵進展
  • 併購
  • 夥伴關係與協作
  • 新產品發布
  • 擴張計劃

第5章：市場估計與預測：按治療類型，2021 - 2034 年

• 主要趨勢
• 藥物治療
  • 依藥物類型
    • 胰島素和抗糖尿病藥物
    • 甲狀腺激素替代療法
    • 腎上腺激素調節劑
    • 生殖荷爾蒙
    • 其他藥物類型
  • 依給藥途徑
    • 口服
    • 注射劑
    • 外用
    • 其他給藥途徑
• 非藥物治療

第6章：市場估計與預測：依疾病類型，2021 - 2034 年

• 主要趨勢
• 糖尿病
• 甲狀腺功能低下症
• 甲狀腺功能亢進
• 庫欣氏症候群
• 艾迪生病
• 生殖障礙
• 其他疾病類型

第7章：市場估計與預測：按動物類型，2021 - 2034 年

• 主要趨勢
• 伴侶動物
  • 狗
  • 貓
  • 其他伴侶動物
• 牲畜
  • 牛
  • 綿羊和山羊
  • 其他牲畜

第8章：市場估計與預測：依最終用途，2021 - 2034 年

• 主要趨勢
• 獸醫醫院和診所
• 零售獸藥局
• 其他最終用途

第9章：市場估計與預測：按地區，2021 - 2034 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第10章：公司簡介

• Boehringer Ingelheim
• Dechra Pharmaceuticals
• Elanco Animal Health
• Kela Health
• Merck
• MedPharm Animal Health
• Med-Pharmex
• Nextmune
• Virbac
• Vivaldis Animal Health
• Zoetis

The Global Veterinary Endocrinology Market was valued at USD 414.5 million in 2024 and is estimated to grow at a CAGR of 6.5% to reach USD 770.3 million by 2034. This market is gaining momentum due to the increasing incidence of hormonal disorders like Cushing's syndrome, diabetes mellitus, and Addison's disease in animals, especially pets. Rising pet ownership rates, coupled with the growing human-animal bond, are driving global demand for pet healthcare. The availability of point-of-care diagnostics expanded access to advanced therapies, and growing awareness around chronic animal diseases has made endocrinology one of the more dynamic segments in veterinary medicine. Ongoing improvements in therapeutic delivery and the demand for long-term disease management across companion and livestock animals are further shaping the market.

Rapid investment in veterinary services and infrastructure in emerging markets across Asia-Pacific and Latin America is also reinforcing industry expansion, as governments and private stakeholders focus on strengthening animal healthcare systems. Increased funding for veterinary clinics, diagnostic laboratories, and telemedicine capabilities is improving access to specialized care, including endocrinology. The rise in companion animal ownership, coupled with a shift toward preventive and chronic disease management in pets, is accelerating demand for advanced hormonal therapies and diagnostic tools. Local production facilities, training of veterinary professionals, and collaborations with multinational pharmaceutical companies are also creating a strong foundation for long-term growth and market penetration in these high-potential regions.

The Pharmacological treatment segment in the veterinary endocrinology market held a 76.5% share in 2024. This segment's leadership stems from widespread adoption due to affordability, long-term use, and consistent outcomes in treating common endocrine disorders in animals. Chronic conditions such as hypothyroidism, diabetes, and adrenal dysfunction typically require sustained medical intervention. Medications used in these treatments benefit from enhanced drug formulations, allowing for improved therapeutic efficacy and better compliance from pet owners. With early diagnosis becoming more routine, especially in urban clinics, drug-based protocols remain the primary line of care across most regions.

Among endocrine disease types, the diabetes mellitus segment will grow at a CAGR of 6.4% through 2034. A key contributing factor is rising pet obesity-particularly among aging cats and dogs-linked to overfeeding and limited physical activity. This has created a continuous demand for advanced diabetes management products and care regimens. Technology has significantly improved disease management, as tools such as long-acting insulin formulations and automated glucose monitoring devices now enable more precise, consistent control of diabetic symptoms in animals. These innovations have elevated both practitioner confidence and owner willingness to engage in treatment.

United States Veterinary Endocrinology Market generated USD 155.1 million in 2024. The country's leadership in the market is largely attributed to early adoption of new technologies, such as CGMs and telehealth services for hormonal disorders, as well as the widespread presence of veterinary specialists focused on endocrinology. Rising cases of hypothyroidism in dogs and diabetes in cats continue to push up demand for diagnostics and targeted therapies. Additionally, growing awareness of obesity-related diseases in pets and a well-established pharmaceutical and regulatory environment help maintain U.S. dominance. Companies with large portfolios and R&D pipelines are accelerating veterinary drug approvals and launching tailored treatments to address these growing needs.

The major players leading the Veterinary Endocrinology Market include Elanco Animal Health, Boehringer Ingelheim, Merck, Dechra Pharmaceuticals, Zoetis, MedPharm Animal Health, Med-Pharmex, Virbac, Kela Health, Vivaldis Animal Health, and Nextmune. These companies continue to innovate while strengthening their global distribution and product lines. Leading veterinary endocrinology companies are actively expanding their product pipelines by investing in long-acting formulations and advanced delivery systems to improve treatment compliance. They are also enhancing their presence in underserved and high-growth regions through strategic partnerships and acquisitions. Companies are focusing on integrated care solutions by combining diagnostics and therapeutics, especially for chronic endocrine disorders like diabetes. Emphasis is placed on training programs for veterinarians and awareness campaigns for pet owners to increase early diagnosis and treatment adoption. Digital tools such as tele-vet platforms and mobile diagnostics are increasingly used to improve access and streamline care.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/Country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Treatment type trends
  • 2.2.3 Disease type trends
  • 2.2.4 Animal type trends
  • 2.2.5 End use trends
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of endocrine disorders in both companion and livestock animals
    • 3.2.1.2 Increasing pet ownership and humanization of pets
    • 3.2.1.3 Rising incidence of obesity in pets
    • 3.2.1.4 Regulatory support and increasing drug approvals
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of treatment and long-term therapy
    • 3.2.2.2 Limited veterinary endocrinology specialists
  • 3.2.3 Market opportunities
    • 3.2.3.1 Growing companion animal population and chronic disease burden
    • 3.2.3.2 Advancement in point-of-care and at-home diagnostics
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
  • 3.4.4 Latin America
  • 3.4.5 Middle East and Africa
• 3.5 Technology landscape
  • 3.5.1 Current technological trends
  • 3.5.2 Emerging technologies
• 3.6 Pricing analysis
• 3.7 Future market trends
• 3.8 GAP analysis
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
  • 4.2.1 Global
  • 4.2.2 North America
  • 4.2.3 Europe
  • 4.2.4 Asia Pacific
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Pharmacological treatment
  • 5.2.1 By drug type
    • 5.2.1.1 Insulin and antidiabetics
    • 5.2.1.2 Thyroid hormone replacement
    • 5.2.1.3 Adrenal hormone modulators
    • 5.2.1.4 Reproductive hormones
    • 5.2.1.5 Other drug types
  • 5.2.2 By route of administration
    • 5.2.2.1 Oral
    • 5.2.2.2 Injectable
    • 5.2.2.3 Topical
    • 5.2.2.4 Other routes of administration
• 5.3 Non-pharmacological treatment

Chapter 6 Market Estimates and Forecast, By Disease Type, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Diabetes mellitus
• 6.3 Hypothyroidism
• 6.4 Hyperthyroidism
• 6.5 Cushing's syndrome
• 6.6 Addison's disease
• 6.7 Reproductive disorders
• 6.8 Other disease types

Chapter 7 Market Estimates and Forecast, By Animal Type, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Companion animals
  • 7.2.1 Dogs
  • 7.2.2 Cats
  • 7.2.3 Other companion animals
• 7.3 Livestock animals
  • 7.3.1 Cattle
  • 7.3.2 Sheep and goats
  • 7.3.3 Other livestock animals

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Veterinary hospitals and clinics
• 8.3 Retail veterinary pharmacies
• 8.4 Other end use

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 India
  • 9.4.3 Japan
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Boehringer Ingelheim
• 10.2 Dechra Pharmaceuticals
• 10.3 Elanco Animal Health
• 10.4 Kela Health
• 10.5 Merck
• 10.6 MedPharm Animal Health
• 10.7 Med-Pharmex
• 10.8 Nextmune
• 10.9 Virbac
• 10.10 Vivaldis Animal Health
• 10.11 Zoetis